The US pharma industry saw a drop of 19.3% in overall deal activity during May 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 67 deals worth $3.66bn were announced in May 2019, compared to the 12-month average of 83 deals.
Venture financing was the leading category in the month in terms of volume with 45 deals which accounted for 67.2% of all deals.
In second place was M&A with 20 deals, followed by private equity with two transactions, respectively accounting for 29.9% and 3% of overall deal activity in the country’s pharma industry during the month.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn terms of value of deals, M&A was the leading deal category in the US pharma industry with total deals worth $2.83bn, while venture financing and private equity deals totalled $795.66m and $40m, respectively.
US pharma industry deals in May 2019: Top deals
The top five pharma industry deals accounted for 79.2% of the overall value during May 2019.
The combined value of the top five pharma industry deals stood at $2.9bn, against the overall value of $3.66bn recorded for the month. The top announced US pharma industry deal tracked by GlobalData in May 2019 was Merck $2.2bn acquisition of Peloton Therapeutics.
In second place was the $400m acquisition of Abide Therapeutics by H. Lundbeck and in third place was EcoR1 Capital, F2 Ventures, Fidelity Management & Research, Gilead Sciences, SVB Leerink, Redmile Group, Samsara BioCapital and Invus Group’s $120m venture financing of AlloVir.
The $90m venture financing of Phathom Pharmaceuticals by Abingworth, BVF Partners, Frazier Healthcare Partners, Greenspring Associates, Janus Henderson Investors, Medicxi Ventures (UK), RA Capital Management, Richard King Mellon Foundation and Sahsen Ventures and Evotec‘s acquisition of Just Biotherapeutics for $90m held fourth and fifth positions, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
